Work

681TiP A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.747

Authors: L.S. Rosen, N. Azad, R. Costa, F. Meric-Bernstam, H. Alaoui, D.M. Jablons, P. Munster, E.P. Hamilton

Institutions: University of California, Los Angeles, Johns Hopkins University, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Sarah Cannon

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, Daiichi Sankyo Europe

OpenAlex ID: W4402560039

FWCI:

Cites:

Cited by:

Related to: 10